Aclarubicin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Aclarubicin
Accession Number
DB11617
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • Aclacinomycin A
External IDs
NSC-208734
Product Ingredients
IngredientUNIICASInChI Key
Aclarubicin hydrochloride501948RI6675443-99-1KUSMIBXCRZTVML-PCCPLWKKSA-N
Categories
UNII
74KXF8I502
CAS number
57576-44-0
Weight
Average: 811.878
Monoisotopic: 811.341520011
Chemical Formula
C42H53NO15
InChI Key
USZYSDMBJDPRIF-SVEJIMAYSA-N
InChI
InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
IUPAC Name
methyl (1R,2R,4S)-4-{[(2R,4S,5S,6S)-4-(dimethylamino)-5-{[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-{[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Aclarubicin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Aclarubicin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumAclarubicin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidAclarubicin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Aclarubicin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmoxicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Aclarubicin.Approved, Investigational
AmpicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumAclarubicin may increase the respiratory depressant activities of Atracurium.Experimental, Investigational
Atracurium besylateAclarubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Aclarubicin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Aclarubicin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BalsalazideBalsalazide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
BendazacBendazac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzydamineBenzydamine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
BenzylpenicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Aclarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Aclarubicin.Approved, Investigational
BevoniumBevonium may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
Botulinum Toxin Type AAclarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BAclarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Aclarubicin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aclarubicin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Aclarubicin.Approved
CarbenicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Aclarubicin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinAclarubicin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Aclarubicin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
CisatracuriumAclarubicin may increase the respiratory depressant activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateAclarubicin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Aclarubicin.Approved
Clodronic AcidAclarubicin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateAclarubicin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Cyclacillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Aclarubicin.Approved, Investigational
CyclosporineAclarubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Aclarubicin.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
DecamethoniumAclarubicin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Aclarubicin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Aclarubicin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Aclarubicin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Aclarubicin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aclarubicin.Approved, Investigational
Domoic AcidAclarubicin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideAclarubicin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aclarubicin.Approved
EtanerceptEtanercept may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
Etidronic acidAclarubicin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
EtoricoxibEtoricoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
exisulindexisulind may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunixinFlunixin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Aclarubicin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Aclarubicin.Approved, Vet Approved
GallamineAclarubicin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideAclarubicin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Aclarubicin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
IbandronateAclarubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Aclarubicin.Experimental
LeflunomideLeflunomide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Aclarubicin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
MecamylamineAclarubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational, Withdrawn
MetampicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Aclarubicin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Aclarubicin.Experimental
MetocurineAclarubicin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideAclarubicin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Aclarubicin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumAclarubicin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Aclarubicin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinAclarubicin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Aclarubicin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Aclarubicin.Approved
OxacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aclarubicin.Approved, Vet Approved
PamidronateAclarubicin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumAclarubicin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Aclarubicin can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Aclarubicin can be decreased when it is combined with Penimepicycline.Experimental
PeruvosidePeruvoside may decrease the cardiotoxic activities of Aclarubicin.Experimental
PhenoxymethylpenicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
PipecuroniumAclarubicin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Aclarubicin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Aclarubicin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Aclarubicin can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental, Investigational
Procaine benzylpenicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Aclarubicin.Experimental
PTC299PTC299 may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
PyrantelAclarubicin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumAclarubicin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Experimental, Investigational
RisedronateAclarubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumAclarubicin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
SuccinylcholineAclarubicin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Aclarubicin can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Aclarubicin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Aclarubicin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateAclarubicin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateAclarubicin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Aclarubicin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Aclarubicin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidAclarubicin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Aclarubicin.Approved
TranilastTranilast may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Aclarubicin.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
TubocurarineAclarubicin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Aclarubicin.Approved
VecuroniumAclarubicin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational
ZileutonZileuton may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidAclarubicin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

General References
  1. Jensen PB, Jensen PS, Demant EJ, Friche E, Sorensen BS, Sehested M, Wassermann K, Vindelov L, Westergaard O, Hansen HH: Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res. 1991 Oct 1;51(19):5093-9. [PubMed:1655244]
  2. Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J: Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun. 2013;4:1908. doi: 10.1038/ncomms2921. [PubMed:23715267]
  3. Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J: Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat Chem Biol. 2015 Jul;11(7):472-80. doi: 10.1038/nchembio.1811. Epub 2015 May 11. [PubMed:25961671]
External Links
KEGG Drug
D02756
KEGG Compound
C18638
PubChem Compound
451415
PubChem Substance
347828010
ChemSpider
397638
BindingDB
50368351
ChEBI
74619
ChEMBL
CHEMBL502620
Wikipedia
Aclarubicin
ATC Codes
L01DB04 — Aclarubicin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentCerebroretinal Vasculopathy, Hereditary / Vasculopathy, Retinal, With Cerebral Leukodystrophy1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Relapsed Leukemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.218 mg/mLALOGPS
logP2.79ALOGPS
logP3.98ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)7.47ChemAxon
pKa (Strongest Basic)8.64ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count15ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area217.05 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity203.87 m3·mol-1ChemAxon
Polarizability84.31 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Anthracyclines
Sub Class
Not Available
Direct Parent
Anthracyclines
Alternative Parents
Tetracenequinones / Aminoglycosides / Anthracenecarboxylic acids / Anthraquinones / Naphthalenecarboxylic acids and derivatives / Disaccharides / O-glycosyl compounds / Tetralins / Aryl ketones / 1-hydroxy-2-unsubstituted benzenoids
show 16 more
Substituents
Anthracyclinone-skeleton / Anthracycline / Tetracenequinone / Aminoglycoside core / Anthracene carboxylic acid or derivatives / Anthracene carboxylic acid / 9,10-anthraquinone / 1,4-anthraquinone / Anthracene / 1-naphthalenecarboxylic acid or derivatives
show 37 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenols, trisaccharide derivative, methyl ester, polyketide, aminoglycoside, anthracycline, tetracenequinones (CHEBI:74619)

Drug created on August 25, 2016 17:13 / Updated on November 09, 2017 04:54